Neurocrine Biosciences ^Partner

Neurocrine Biosciences is a biopharmaceutical company based in San Diego, California, founded in 1992. With over 1,700 employees, the company focuses on developing treatments for neurological and endocrine-related disorders. Neurocrine conducts extensive clinical trials and research in areas such as movement disorders, epilepsy, and congenital adrenal hyperplasia, often collaborating with other pharmaceutical companies to enhance its product development and distribution.

The company offers several FDA-approved treatments, including Ingrezza, a medication for tardive dyskinesia and chorea associated with Huntington’s disease, and ORILISSA, which is used to treat endometriosis-associated pain. Neurocrine also provides treatments for classic congenital adrenal hyperplasia, addressing the needs of patients with rare and under-addressed diseases. Their mission emphasizes a commitment to scientific excellence and patient-centricity, aiming to improve access to innovative therapies for underserved populations.